PCA
TXG icon

Prosperity Capital Advisors’s 10x Genomics TXG Stock Holding History

Prosperity Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,246
Closed -$155K – 453
2025
Q3 		$155K Buy
+13,246
New +$173K 0.01% 407

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prosperity Capital Advisors's TXG Position: Q4 2025 in Review

Prosperity Capital Advisors sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 13,246 shares — an estimated $155K sold.

Prosperity Capital Advisors first reported a position in TXG in Q3 2025 and held it in 1 quarter. The position peaked at $155K in Q3 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Prosperity Capital Advisors reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Prosperity Capital Advisors sold 13,246 10x Genomics shares in Q4 2025, an estimated $155K.
  • Prosperity Capital Advisors first reported a position in 10x Genomics in Q3 2025 and held it in 1 quarter.
  • Prosperity Capital Advisors's 10x Genomics position peaked at $155K in Q3 2025.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Prosperity Capital Advisors's 13F filing for Q4 2025, filed 20 Jan 2026.